KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Non-Current Assets (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Non-Current Assets for 6 consecutive years, with $660.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets rose 1.68% year-over-year to $660.9 million, compared with a TTM value of $660.9 million through Sep 2025, up 1.68%, and an annual FY2024 reading of $609.2 million, down 1.12% over the prior year.
  • Non-Current Assets was $660.9 million for Q3 2025 at AbCellera Biologics, roughly flat from $659.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $660.9 million in Q3 2025 and bottomed at $220.5 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $525.1 million, with a median of $579.2 million recorded in 2025.
  • The sharpest move saw Non-Current Assets skyrocketed 102.26% in 2021, then decreased 10.77% in 2025.
  • Year by year, Non-Current Assets stood at $388.8 million in 2021, then skyrocketed by 32.58% to $515.4 million in 2022, then increased by 19.54% to $616.1 million in 2023, then decreased by 1.12% to $609.2 million in 2024, then rose by 8.48% to $660.9 million in 2025.
  • Business Quant data shows Non-Current Assets for ABCL at $660.9 million in Q3 2025, $659.9 million in Q2 2025, and $579.2 million in Q1 2025.